Alnylam Pharmaceuticals IncFind Ratings Reports
ALNYLAM PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALNYLAM PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 8.63 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 2.22% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||15.93||8.71|
|Net Income ($mil)||-118.42||-90.13|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||923.27||856.4|
|Total Assets ($mil)||1434.28||1382.16|
|Total Debt ($mil)||150.0||150.0|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||-736.93||-1015.49|
|Return on Assets||-30.86||-26.09|
|Return on Equity||-39.42||-32.82|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||91.7||85.57|
|Div / share||0.0||0.0|
|Book value / share||12.25||12.84|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||893893.0||1043422.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 6.38 indicates a significant premium versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, ALNYLAM PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives within the industry.
|ALNY NM||Peers 39.88||ALNY NM||Peers 27.93|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ALNY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALNY's P/CF is negative making the measure meaningless.
|ALNY NM||Peers 25.67||ALNY NA||Peers 0.50|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ALNY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ALNY 6.38||Peers 12.14||ALNY -20.75||Peers 10.47|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALNY is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ALNY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ALNY 108.58||Peers 94.57||ALNY 120.51||Peers 233.22|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALNY is trading at a premium to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALNY significantly trails its peers on the basis of sales growth